Clinical Trial Update: The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals

View source ↗

Summary

A clinical trial evaluating the use of the ultrasound contrast agent Optison to enhance tricuspid regurgitation Doppler signals has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension

Drugs mentioned

• Optison

Snippet

Sponsor: Northwell Health | Conditions: Hypertension, Pulmonary | Status: WITHDRAWN